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Abstract
The epithelial-mesenchymal transition (EMT) program has emerged as a central driver of tumor 
malignancy. Moreover, the recently uncovered link between passage through an EMT and 
acquisition of stem-like properties indicates that activation of the EMT programs serves as a major 
mechanism for generating cancer stem cells, i.e., the cells that are responsible for initiating and 
propagating the disease. In this review, we summarize the evidence supporting the widespread 
involvement of the EMT program in tumor pathogenesis and attempt to rationalize the connection 
between the EMT program and acquisition of stem-cell traits. We propose that the epithelial-
mesenchymal plasticity is likely controlled by multiple varients of the core EMT program and 
foresee the need to resolve the various programs and the molecular mechanisms that underlie 
them.
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The EMT is a naturally occurring transdifferentiation program
The successes over the past decade in reprogramming the terminally differentiated cells of 
normal adult tissues into pluripotent stem cells (Takahashi and Yamanaka, 2006; Yu et al., 
2007) have led to the widely embraced assumption that almost any type of dedifferentiation 
or transdifferentiation is possible, if only the proper combination of ectopically expressed 
transcription factors is introduced into adult cells. These successes in experimental 
reprogramming raise the question of which changes in cell state actually occur in nature 
rather than being artifacts of experimentally forced ectopic gene expression.
*Correspondence: weinberg@wi.mit.edu (R.A.W.). 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Trends Cell Biol. Author manuscript; available in PMC 2016 November 01.
Published in final edited form as:
Trends Cell Biol. 2015 November ; 25(11): 675–686. doi:10.1016/j.tcb.2015.07.012.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Foremost among the naturally occurring transdifferentiation programs is the cell-biological 
program termed the epithelial-mesenchymal transition (EMT), which converts epithelial 
cells into more mesenchymal derivatives, and the reverse of this program, termed the 
mesenchymal-epithelial transition (MET) (Nieto, 2013). Evidence accumulated over the past 
two decades indicates clearly that this program operates during development to ensure the 
interconversions of cells that are required to form various distinct cell types and thus the 
tissues and organs of complex metazoans (Nieto, 2013; Thiery et al., 2009). This cell-
biological program is orchestrated by a cohort of transcription factors (EMT-TFs), including 
those of Snail, Twist and Zeb families (Nieto, 2011; Thiery et al., 2009).
Two additional aspects of the EMT program are worthy of detailed examination: In some 
epithelial tissues the EMT program seems to be linked to residence of cells in stem cell-like 
states. In addition, versions of the EMT program are coopted by cancer cells, enabling them 
to acquire cellular traits associated with high-grade malignancy. These ramifications of the 
EMT program have revealed previously unapparent mechanistic connections between 
ontogeny and tumor pathogenesis.
The EMT program and epithelial-mesenchymal plasticity
The EMT program, as its name implies, governs changes of cell states along the epithelial 
versus mesenchymal axis and converts epithelial cells to mesenchymal cells when this 
program is fully executed. To describe the extremes poles of the epithelial vs. mesenchymal 
axis (Table 1), one notes that epithelial cells, often with polygonal shapes in monolayer 
culture, are polarized along their apical-basal axis and are tightly connected to one another 
laterally via adherens and tight junctions; in vivo these lateral ties ensure the structural 
integrity of epithelial cell sheets. Fully mesenchymal cells, in stark contrast, exhibit spindle-
like morphology with no signs of apical-basal polarity and are loosely attached to the 
surrounding extracellular matrix through focal adhesions; these features help to explain their 
heightened motility and invasiveness relative to their epithelial counterparts.
The profound biological distinctions between epithelial cells and mesenchymal cells are 
determined by differences in their respective transcription programs, which control, among 
other gene products, the expression of key structural proteins, including those involved in 
maintaining the cytoskeleton and in forging cell-cell adhesions (Nieto, 2011, 2013; Thiery et 
al., 2009). Thus, epithelial cells express various types of cytokeratins which form their 
intermediate filaments, whereas the mesenchymal cells express instead the intermediate 
filament protein vimentin. The expression of cell-cell adhesion molecules and polarization 
complexes is generally repressed in mesenchymal cells. A hallmark of EMT is the 
replacement of E-cadherin by N-cadherin, which results in the formation of far weaker cell-
cell adhesions between adjacent cells.
The EMT program can be activated with remarkable rapidity in epithelial cells in response 
to physiologic signals in both a cell-autonomous and non-cell-autonomous manner. Using 
gastrulation as an example, the EMT program is activated in the epithelial cells in the 
epiblast and completely converts epithelial cells to mesenchymal cells of the mesoderm in 
response to inductive signals, such as FGFs (fibroblast growth factors) and Wnt Signaling 
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pathways (Tam and Behringer, 1997). Similarly, in adult tissues, the EMT program is 
activated quickly in response to wounding, facilitating rapid closure of the wounds and 
reestablishment of the epithelial barriers that are essential for protecting the interior of the 
organs from external insults (Savagner 2005). Such rapid interconversion between the 
epithelial and mesenchymal states implies plasticity in epithelial cells that render them 
highly responsive to EMT-inducing signals. Moreover, this plasticity suggests that residence 
in one of these two states is maintained in a metastable fashion, with complex molecular and 
cellular mechanisms operating to ensure long-term residence in one state or the other.
The depiction of the EMT program as a binary switch that moves cells from a fully 
epithelial to a fully mesenchymal state misrepresents the normal actions of this program, 
which usually moves cells from a fully epithelial state to one that is partially mesenchymal, 
with retention of certain key epithelial markers (Grunert et al., 2003; Theveneau et al., 
2010). Nonetheless, the acquisition of even a subset of mesenchymal traits endows cells that 
previously resided in a fully epithelial state with a suite of mesenchymal traits that exert 
profound effects on their biology.
EMT and the normal epithelial stem-cell state
Over the past five years a series of discoveries has converged on the conclusion that after 
epithelial cells pass, at least partially, through an EMT, they are poised to enter into an 
epithelial stem-cell state. At least in the context of mammary epithelial cells, this holds true 
for both normal and neoplastic cells (Guo et al., 2012; Mani et al., 2008; Morel et al., 2012; 
Morel et al., 2008; Scheel et al., 2011). Given the biological similarities among diverse 
epithelial cell types (Blanpain et al., 2007), it seems plausible that versions of this scenario 
are likely to hold true in other epithelial tissues as well.
The stemness of epithelial cells can be demonstrated by their ability to reconstitute their 
tissue-of-origin after transplantation into a suitable microenvironment (Blanpain et al., 
2007). For instance, the stemness of normal mammary epithelial cells can be gauged by 
implanting candidate cells into cleared mammary stromal fat pads, i.e., the structures from 
which the incipient mammary ductal trees present in young female mice have been 
surgically removed. Following implantation of bona fide mammary stem cells, entire 
mammary ductal trees will grow out over a period of six to eight weeks that are 
indistinguishable from those formed during normal mammary gland morphogenesis 
(Shackleton et al., 2006; Stingl et al., 2006). Such success in gland formation provides a 
rigorous test of stemness, in that candidate stem cells can be shown to create a complete 
adult organ. In the one case reported to date, forcing a population of normal murine 
mammary epithelial cells through an EMT, achieved through the combined actions of the 
transiently expressed Slug and Sox9 EMT-TFs, increased the representation of mammary 
stem cells within heterogeneous populations of mammary epithelial cells by two orders-of-
magnitude, as gauged by this mammary gland reconstitution assay (Guo et al., 2012).
Of additional relevance here is the observation that the Slug EMT-TF is expressed in the 
basal/abluminal layer of normal murine and human mammary ducts at sites where normal 
mammary stem cells are proposed to reside (Guo et al., 2012; Nassour et al., 2012). 
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Moreover, qRT-PCR quantification of FACS (fluorescence-activated cell sorting)-enriched 
mammary stem cells demonstrates that the mammary stem cells residing within normal 
mammary ducts expresses the Slug EMT-TF at levels that are more than two orders-of-
magnitude higher per cell than the differentiated luminal epithelial cell population (Guo et 
al., 2012). These observations suggest that at least one component of the EMT program 
operates in normal tissues in the absence of pathology such as wound healing or neoplasia.
The biological rationale of the connection between EMT and stemness is not so easily 
constructed. It would seem to represent a cell-biological relationship that dates back to the 
inception of metazoan phyla rather than being a recent invention of mammals. One insight 
may come from considerations of how wound healing occurs in epithelial tissues. Closure of 
the wound involves the movement of epithelial cells into the gap, their proliferation, and 
ultimately their assembling of lateral connections, such as adherens junctions. Cells that are 
entirely epithelial are thought to be poorly motile in contrast to their mesenchymal 
counterparts, suggesting that cells at the edges of wounds need to activate, at least partially, 
an EMT program. Indeed, the experimental scarring of a human keratinocyte monolayer in 
vitro provokes the expression of the Slug EMT-TFs in the epithelial cells lining the edges of 
the newly formed gap (Savagner et al., 2005). In mice, Slug expression is elevated in 
keratinocytes lining the cutaneous wound margins in vivo, and epithelial outgrowth and 
wound closure is impaired in keratinocytes isolated from Slug knock-out mice (Shirley et 
al., 2010). These observations suggest that transient expression of an EMT program is 
intrinsic to epithelial wound healing. At the same time, the cells that are participating in 
reconstructing a damaged epithelium need to undergo a burst of proliferation in order to 
expeditiously fill the vacant area. This rapid proliferation may require the generation of new 
stem cells such as those created by activation of an EMT program. Following migration into 
wound sites and rapid increases in the sizes of epithelial cell populations, intrinsic epithelial-
mesenchymal plasticity allows the cells that have undergone a partial EMT to revert back to 
an epithelial state via MET in order to successfully reconstruct the epithelial cell layer; such 
METs are likely to be accompanied by declines in the sizes of stem cell populations. While 
imprecise and conjectural at present, a rationale such as this one may eventually be found to 
explain the previously unanticipated connection between the EMT program and epithelial 
stem-cell properties.
EMT and cancer pathogenesis
Almost 80% of life-threatening human malignancies derive from epithelial tissues, 
generating a wide array of commonly occurring carcinomas, including tumors of the lung, 
colon, breast, pancreas, prostate, bladder, ovary, kidney and liver. In each case, the epithelial 
states of the corresponding normal cells-of-origin dictate that early-stage tumors arising in 
these tissues continue to express the cytokeratins and E-cadherin that are hallmarks of the 
epithelial state. In addition, neoplastic cells in these early tumors retain expression of the 
key biological phenotypes of epithelial cells, such as a lack of motility and an ability to form 
continuous cell sheets. These traits contrast starkly with those of cells present in advanced 
carcinomas, which arise as products of a complex succession of steps that is often termed 
tumor progression. Cells of the highly aggressive primary tumors display mesenchymal 
features, including motility and invasiveness, the latter of which is associated with 
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metastatic dissemination (Huber et al., 2005; Morel et al., 2012; Rhim et al., 2012; Sarrio et 
al., 2008). At the mechanistic level, the acquisition of these malignant traits can be 
explained by the activation within carcinoma cells of previously latent EMT programs 
during tumor progression.
Taking breast cancer as an example, acquisition of mesenchymal features is positively 
associated with more aggressive subtypes of this disease and tumor progression 
(Aleskandarany et al., 2014; Blanco et al., 2002; Blick et al., 2008; Choi et al., 2013). More 
direct demonstrations of the link between EMT activation and tumor malignancy comes 
from a large body of loss-of-function and gain-of-function studies in xenograft tumor 
models. In both human and mouse breast cancer cell lines, depletion of EMT-TFs, such as 
Twist, Snail and Zeb1, greatly inhibits metastatic dissemination both from sites of primary 
tumor formation (e.g., the mammary stromal fat pad) and after experimental introduction of 
carcinoma cells into the venous circulation (i.e., tail-vein injection). Conversely, ectopic 
activation of the EMT program through forced expression of EMT-TFs can enhance 
metastatic dissemination of orthotopically implanted human breast cancer cells (Guo et al., 
2012; Roy et al., 2014; Wu et al., 2009; Yang et al., 2004; Zhang et al., 2013; Tran et al., 
2014).
Besides promoting systemic dissemination, the EMT program also appears to serve as a 
major driver of drug resistance and subsequent disease recurrence in breast cancer patients 
(Cheng et al., 2014; Creighton et al., 2009; Oliveras-Ferraros et al., 2012). Similarly, in a 
mouse model of Her2-induced tumors, the Snail EMT-TF is spontaneously activated in 
recurrent tumors in vivo and confers on them a highly mesenchymal phenotype (Moody et 
al., 2005), providing additional support of the causal relationship between EMT activation 
and tumor relapse. The connection between EMT activation and enhanced tumorigenicity 
has been confirmed in a variety of human cancer cell lines (Creighton et al., 2010). More 
recently, inhibition of epithelial-mesenchymal plasticity by blocking activation of the Zeb1 
EMT-TF efficiently suppressed transition of carcinoma cells from a weakly tumorigenic into 
a highly tumorigenic state, i.e., into a state where they exhibit increases in their tumor-
initiating capability (Chaffer et al., 2013).
Intriguingly, a number of recent studies have connected activation of the EMT program to 
acquisition of immunosuppressive capabilities in a variety of cancers. In melanoma, 
expression of the Snail EMT-TF can simultaneously inhibit differentiation of cytotoxic T 
cells and induce the formation of immunosuppressive regulatory T cells, the latter effect 
being mediated through production of thrombospondin (Kudo-Saito et al., 2009). In breast 
cancer cells, the EMT program enhances resistance of tumor cells to cytotoxic T cell-
mediated lysis, at least in part by inducing autophagy (Akalay et al., 2013; Akalay et al., 
2015). In lung cancer cells, activation of the EMT-TF Zeb1 has been linked to increases in 
PD-L1 expression, a known immune-suppressive molecule that can block the attack of 
tumor-infiltrating lymphocytes (Chen et al., 2014).
Given the pleiotropic functions of EMT activation in driving cancer progression and the 
growing reports of its association with various types of aggressive carcinoma cells, it is now 
plausible that essentially all carcinomas develop malignancy-associated traits through 
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activation of an EMT program in their constituent neoplastic cells. However, this statement 
of widespread association of EMT with various cancers needs to be qualified, as many 
clinical pathologists dispute the existence of this program and its role in generating high-
grade carcinomas (Tarin et al., 2005). A substantial part of this reluctance appears to derive 
from the fact that at the technical level, the repertoire of markers used to score clinical tissue 
sections often makes it difficult if not impossible to distinguish bona fide carcinoma cells 
that have undergone an EMT from adjacent recruited tumor-associated stromal cells derived 
from normal host tissues, many of which are fibroblasts and myofibroblasts, which naturally 
express EMT-associated markers. Since carcinoma cells often undergo a partial EMT, clear 
evidence of the involvement of this program in tumor progression can derive from the 
detection of cells that co-express acquired mesenchymal traits with certain retained 
epithelial markers inherited from their fully epithelial precursors. Indeed, recent analyses of 
human breast cancer specimens by in situ hybridization of pooled epithelial and 
mesenchymal markers has revealed the existence of tumor cells with both epithelial and 
mesenchymal features in invasive breast cancers of all subtypes (Yu et al., 2013). Moreover, 
a significant fraction of circulating tumor cells isolated from the peripheral blood of human 
patients with advanced prostate and breast cancers also co-express both epithelial and 
mesenchymal markers (Husemann et al., 2008; Raimondi et al., 2011; Yu et al., 2013).
The apparent widespread involvement of EMT in the pathogenesis of carcinomas raises the 
question of its contribution to the non-carcinomatous tumors encountered in the clinic. 
Neuroectodermal tumors, such as gliomas and glioblastomas, often give evidence of having 
passed through at least a partial EMT by exhibiting certain mesenchymal markers, including 
expression of a variety of EMT-TFs (Kahlert et al., 2013; Tso et al., 2006). From the 
perspective of developmental biology, one can rationalize this behavior by citing the distant 
origins of these tumors from a primitive epithelium – the neuroectoderm. However, the 
progression of tumors representing the other two major classes of cancers – hematopoietic 
and mesenchymal/sarcomatous – does not seem to involve activation of EMT programs. 
Instead, at least in the case of sarcomas, the corresponding normal cells-of-origin – plausibly 
cells akin to fibroblasts or mesenchymal stem cells (MSCs), express a variety of EMT-TFs 
constitutively, ostensibly to maintain their residence in a fully mesenchymal state (Chang et 
al., 2002). When viewed from this perspective, one can propose that ancestors of the normal 
cells-of-origin of sarcomas underwent EMTs early in ontogeny, long before the inception of 
tumor development. Indeed, primitive connective tissue cells, i.e., cells similar to MSCs, can 
be created experimentally by forcing epithelial cells through a complete EMT program that 
erases all traces of their epithelial origins and replaces them entirely with mesenchymal ones 
(Battula et al., 2010).
The EMT and entrance into the cancer stem cell state
Cellular heterogeneity has been widely reported in a variety of hematopoietic and solid 
cancers. One prominent feature of the cellular heterogeneity involves the differing degrees 
of tumor-initiating potential exhibited by various cancer cells coexisting within the same 
tumor. These more tumorigenic cells are termed tumor-initiating cells, or cancer stem cells 
(CSCs), as they resemble normal stem cells in terms of the ability to self-renew and generate 
more differentiated derivatives. The presence of CSCs is best quantified experimentally by 
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implanting tumor cells at limiting dilutions into appropriate mouse hosts and scoring 
thereafter for any observed tumor formation. By such measures, forcing bulk populations of 
human breast cancer cells through an EMT by transient expression of EMT-TFs can increase 
the frequency of tumor-initiating breast CSCs (Guo et al., 2012; Mani et al., 2008; Morel et 
al., 2008), indicating that EMT programs play roles in facilitating the entrance of non-stem 
cells into stem-cell states in both normal and neoplastic mammary tissues. We note that the 
cited studies, virtually all of which have involved the experimental activation of EMT-TFs, 
do not take into account the fact that EMT-TFs are often naturally activated in temporal 
hierarchies and that they cooperate with one another to drive EMT progression in various 
physiologic settings (Nieto, 2013). This contrasts with the experimental methods reported to 
date, in which either the temporal sequence or the levels of ectopically expressed EMT-TF 
have usually deviated strongly from those controlled by normal physiologic regulation. 
Accordingly, the reported increases in CSC activity following induction of an EMT might 
actually be far higher if such experiments were performed under more optimal, 
physiologically appropriate conditions.
Given the multiple successive steps that occur during the tumor progression that leads from 
normal to highly malignant cells, it seems plausible that each cell population formed during 
each of the intermediate stages of carcinoma progression (i.e., hyperplastic, dysplastic, 
adenomatous, etc.) contains its own subpopulation of stem cells. These subpopulations 
should presumably depend on specific versions of the stem-cell program operating either in 
the fully normal or in the fully neoplastic cell populations within a specific tissue. In order to 
equip the tumor cells of each intermediate stage with desired combinations of epithelial and 
mesenchymal traits and maintain their epithelial-mesenchymal plasticity, these versions of 
stem-cell programs may potentially engage different combinations of EMT-TFs to achieve 
different levels of EMT activation. Retention of such plasticity appears to be important, 
since some have found that constitutive expression of strong EMT-inducers, such as Twist 
and Prrx1, blocks epithelial-mesenchymal plasticity, thereby precluding the MET that 
appear to be critical to the ability of carcinoma cells to establish new tumors or metastatic 
colonies (Ocana et al., 2012; Stankic et al., 2013; Tran et al., 2014; Tsai et al., 2012). In 
contrast, transient activation of an EMT program enables normal and neoplastic mammary 
epithelial cells to enter into the stem-cell state, possibly through enhancing their epithelial-
mesenchymal plasticity (Schmidt et al., 2015). For these reasons, it appears that carcinoma 
CSCs (as well as the corresponding normal stem cells) reside in a phenotypic state that 
combines both epithelial and mesenchymal features and, at the same time, permits these 
cells to move into alternative states lying along the epithelial-mesenchymal axis. If 
validated, this would indicate that normal stem cells reside in a state that is quite distinct 
from that of bona fide mesenchymal cells, which lie at the extreme pole of the epithelial-
mesenchymal axis.
Contextual signals inducing an EMT in carcinoma cells
The patterns of activation of EMTs during development dictate that this program must be 
expressed in response to contextual signals experienced by individual cells in various 
locations within developing embryos. By extension, related patterns of heterotypic signaling 
must also operate during wound healing and tumor progression to activate this program. In 
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certain carcinomas, the expression of EMT programs can often be observed among 
carcinoma cells that are closely apposed to stromal cells, specifically cells forming the 
“reactive stroma” that is developed late in tumor progression. Included among the cells of 
the late-stage stroma are not only the dominant fibroblasts and myofibroblasts, but cell types 
associated with wound healing and inflammation, such as MSCs, macrophages, and 
lymphocytes.
Once activated, continued expression of an EMT program within a carcinoma cell may 
depend on continuous paracrine signals received from the stroma; such dependence dictates 
that carcinoma cells will lapse back into an epithelial state (via an MET) when they no 
longer experience these inductive signals. Alternatively, carcinoma cells that have activated 
an EMT program may maintain its continued expression in a cell-autonomous manner, 
doing so via self-reinforcing, positive-feedback loops (Scheel et al., 2011). Among these 
heterotypic paracrine signals is the well-described cytokine TGF-β, which has been shown 
to be released predominantly by myofibroblasts (Oft et al., 1998). In addition, a diverse 
array of alternative signaling molecules has also been observed to participate in EMT 
induction, including morphogens such as Wnt, Notch, Shh, cytokines, prostaglandin E2, and 
growth factors such as EGF, FGF, HGF, PDGF, and VEGF (Thiery et al., 2009). Under 
many circumstances, the EMT programs are activated in response to several distinct 
paracrine signals acting in combination (Thiery et al., 2009) to ensure that an EMT is only 
activated when several distinct prerequisites have been met in individual cells. In the context 
of normal development, such an arrangement ensures that activation of EMT programs will 
be confined to discrete sectors within embryos. In the context of tumor progression, a 
variety of stromal cell-derived signals synergize with one another to induce and maintain 
EMTs in primary tumors (Fig. 1). Indeed, prostaglandin E2 (PGE2) can be secreted by 
fibroblasts, myofibroblasts, and MSCs (Li et al., 2012), while CCL18 and Ephrin is 
presented by monocytes and macrophages (Lu et al., 2014; Su et al., 2014), and TGF-β is 
released from myofibroblasts and platelets (Labelle et al., 2011). In certain experimental 
models, inhibition of any of these signals could suppress EMT activation and greatly 
attenuate tumor initiation and metastases in various xenograft tumor models, reflecting the 
fact that EMT is a highly coordinated process requiring the combinatorial actions of multiple 
contextual signals.
The diversity of EMT-inducing signals enumerated above impinge upon and activate an 
array of EMT-TFs, which, as mentioned, include members of the Snail family, Twist family, 
Zeb family, FOX family of proteins and others (Thiery et al., 2009). Such diversity suggests 
that different versions of the EMT program could in theory operate in different tissues 
during developmental morphogenesis, and that distinct variants of this program may 
function during the progression of different types of carcinomas. Moreover, a number of 
posttranscriptional and epigenetic mechanisms are employed to ensure that the EMT 
program is precisely regulated and robustly executed. For instance, transcription factors of 
the Zeb family form a double-negative feedback loop with the miR-200 family of 
microRNAs, causing this regulatory loop to operate as a bi-stable switch between the 
epithelial and mesenchymal state in a variety of carcinomas (Brabletz and Brabletz, 2010; 
Burk et al., 2008; Hill et al., 2013). Similarly, Snail represses the expression of miR-34, a 
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miRNA that otherwise can bind to the 3’ UTR of the Snail mRNA and cause its degradation 
(Brabletz, 2012; Kim et al., 2011). The EMT program also elicits profound changes in the 
transcriptome within a cell by altering the expression of splicing factors, including that of 
the ESRP (epithelial splicing regulatory proteins), RBFOX, MBNL (Muscleblind-like), 
CELF (CUG-BP- and ETR-3-like factors), and hnRNP (heterogeneous nuclear 
ribonucleoproteins) families, thereby promoting production of mRNA isoforms specific to 
the mesenchymal state (Shapiro et al., 2011).
Beyond the level of mRNAs, EMT-TFs can alter chromatin configurations to achieve stable, 
long-term silencing of epithelial genes as cells pass through a complete EMT (reviewed in 
Tam and Weinberg, 2013). For example, Snail can recruit a series of chromatin-modifying 
enzymes to the E-cadherin promoter to erase a critical mark of active transcription 
(trimethylated H3K4) and leave in its stead a trimethylated H3K9 mark. Such a 
trimethylated H3K9 mark could promote the recruitment of DNA methyltransferases 
(DNMTs), in turn causing CpG methylation of the promoter and formation of a constitutive 
heterochromatin that is highly resistant to transcription activation (Lin et al., 2014).
Besides these conventional modes of regulation, a recent report has suggested that metabolic 
reprogramming serves as an additional self-reinforcing mechanism of the EMT program 
(Shaul et al., 2014). In particular, induction of the EMT program in human breast cancer 
cells drove expression of the pyrimidine-degrading enzyme dihydropyrimidine 
dehydrogenase (DPYD), which led to an accumulation of its enzymatic products, 
dihydropyrimidines, in cells with mesenchymal features. This metabolic change is required 
for efficient activation and ongoing expression of an EMT program, because shRNA-
mediated silencing of DPYD or reduction of intracellular dihydropyrimidine concentrations 
attenuated entrance into the mesenchymal state and acquisition of invasive and metastatic 
features.
EMT, epithelial-mesenchymal plasticity and the invasion-metastasis 
cascade
The later stages of malignant progression of carcinomas have been portrayed as a succession 
of steps termed the invasion-metastasis cascade (Fidler, 1978; Fidler, 2003). Thus, 
carcinoma cells within primary tumors acquire invasiveness, intravasate into microvessels 
within these tumors, circulate to distant anatomical sites (hematogenous dissemination), 
lodge in microvessels of such distant tissues, invade through the walls of microvessels into 
the parenchyma of these distant tissues (extravasation), seed the formation of 
micrometastatic deposits, and occasionally spawn macroscopic, clinically apparent 
metastases. This last step – often termed colonization – occurs with low efficiency. A 
variant of this cascade portrays the lymph nodes that drain sites of primary tumor formation 
as temporary staging areas in which cancer cells initially collect via the draining lymph 
ducts of a tumor, proliferate in these sites, and thereafter disseminate hematogenously to 
more distant tissues.
While a multitude of genetic and heritable epigenetic alterations have been found to play 
critical roles in driving primary tumor formation, the contributions of these changes to 
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completion of the multiple steps of the invasion-metastasis cascade remain unclear. It is 
possible that the mutations that are responsible for primary tumor formation do not enable 
carcinoma cells to complete the various steps of this cascade; instead, additional mutant 
alleles are required to drive cells into metastatic dissemination. Alternatively the genetic 
(and heritable epigenetic) alterations carried by primary tumor cells may already suffice to 
empower these cells to disseminate; according to this second scenario, certain changes in 
epigenetic programs may, on their own, propel primary carcinoma cells to distant 
anatomical sites.
If the second scenario were validated, it would imply that carcinoma cells within primary 
tumors are already genetically equipped to disseminate and thus do not require additional 
mutations beyond those selected during primary tumor formation. This portrayal becomes 
increasingly plausible in light of recent evidence. The induced expression of EMT-TFs in 
primary, otherwise-non-metastatic tumor cells can increase the ability of these cells to seed 
lung metastases without the need for additional genetic changes (Mani et al., 2008; Morel et 
al., 2012; Morel et al., 2008). Moreover, and less directly, the incubation time required for 
colorectal adenomatous polyps to spawn full-blown primary colorectal carcinomas has been 
estimated to be ~17 years; however, following this, a period of two years or less has been 
found to suffice before liver metastases of these tumors can be detected (Calabrese et al., 
2004; Jones et al., 2008). This finding might suggest that rare mutations are needed for 
polyp-to-carcinoma progression to occur, explaining the long lag time associated with this 
progression while, in contrast, certain rapidly acquired epigenetic changes, such as the 
activation of a latent EMT-TF program, may enable primary colorectal carcinoma cells to 
spread to the liver. Still, neither of these lines of evidence –both preclinical and clinical – 
provide rigorous proof that epigenetic activation of a previously silent transcription 
program, specifically EMT, suffices to enable primary carcinoma cells to disseminate to 
distant sites.
The last step of the invasion-metastasis cascade –colonization – does not seem to fall within 
the purview of the EMT program. Thus, this growth of micro- into macroscopic metastases 
would seem to require, among other things, the adaptation of cells arising in one fully 
differentiated tissue to the foreign and potentially inhospitable microenvironment of a 
second, quite distinct differentiated tissue. For example, why should breast carcinoma cells, 
which arise and develop in the tissue microenvironment of the mammary gland, be equipped 
to survive and proliferate in the microenvironments of unfamiliar tissues, such as those of 
the brain, lung, liver or bone marrow? The known functions of the EMT would not seem to 
confer such adaptive powers, suggesting that disseminated cells must invent such 
adaptations on their own following their arrival at distant tissues (Klein 2009). Indeed, it is 
plausible that such an adaptive program contrived by the disseminated carcinoma cells in 
one patient is unique, being cobbled together on an ad hoc basis by assembling components 
of various differentiation programs; accordingly, the bone marrow metastases arising in one 
breast cancer patient may invent a different adaptive program than those formed in another 
patient suffering the same disease. The fact that these adaptations are difficult to acquire 
would seem to be suggested by the astronomically low likelihood of successful colonization 
(Cameron et al., 2000; Chambers et al., 2002; Luzzi et al., 1998).
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Although it remains obscure whether the tissue-specific adaptations are acquired through 
either epigenetic or genetic means, accumulating evidence suggests that METs are required 
for successful metastatic colonization. Indeed, distant metastases encountered in human 
carcinoma patients often manifest the epithelial features and even architectural organization 
of their correspondent tissues-of-origin. Thus, the quasi-mesenchymal cells that serve as the 
founders of metastatic colonies must be able to spawn large numbers of epithelial progeny to 
recreate the hierarchical relationships of CSCs and non-CSC that previously operated within 
the corresponding primary tumors (Malanchi et al., 2012; Thiery, 2002). Moreover, several 
reports using different tumor models or cell line systems have converged on the conclusion 
that constitutive activation of strong EMT programs will block MET, and prevent 
colonization of tumor cells at the metastatic sites (Ocana et al., 2012; Stankic et al., 2013; 
Tsai et al., 2012). These observations indicate that the epithelial-mesenchymal plasticity lies 
at the heart of tumor development, and that such plasticity is opportunistically exploited by 
carcinoma cells to accomplish the last step of the metastatic cascade -- colonization. This is 
reminiscent of the dynamic inter-conversions between the epithelial and mesenchymal states 
during embryogenesis, where EMT and subsequent MET is required for the proper 
development of mesoderm-derived epithelial structures, such as the collecting ducts of the 
kidney (derived from the intermediate mesoderm) and the mesothelial membranes (derived 
from the lateral plate mesoderm).
Concluding remarks
The connection made between activation of the EMT program and entrance into a CSC state 
has placed the EMT program as a central regulator of carcinoma progression. Thus, besides 
the conventional depiction of the EMT program as a driver of metastatic dissemination, 
activation of the EMT program can directly enhance tumor-initiation, thereby creating 
metastatic CSCs. Moreover, intrinsic epithelial-mesenchymal plasticity enables cancer cells 
to switch between the mesenchymal CSC state and a more differentiated, more rapidly 
proliferating epithelial state, thereby creating one important dimension of intra-tumoral 
heterogeneity (Chaffer et al., 2011; Chaffer et al., 2013; Gupta et al., 2011). This epithelial-
mesenchymal plasticity implies that tumor cells can reside in a partial mesenchymal state 
and display various combinations of epithelial and mesenchymal features (Tam and 
Weinberg, 2013). Moreover, CSCs have been found to exhibit a heightened resistance to a 
variety of existing treatments, including radio-and chemotherapy in various carcinoma types 
(Creighton et al., 2009; Singh and Settleman, 2010). This resistance causes enrichment of 
the more mesenchymal, stem-like cancer cells after initial treatment, which can often give 
rise to clinical relapse (Gupta et al., 2009). These considerations explain why the EMT and 
the CSC programs are increasingly attracting the attentions of those involved in finding new 
ways to clinically treat advanced carcinomas, almost all of which, sooner or later, generate 
growths that evade treatments and prove lethal to those carrying them.
These metastable, partial mesenchymal states arising in a diverse array of carcinomas are 
likely controlled by multiple alternative variants of the core EMT program, which differ 
from one another in EMT-TF usage, epigenetic and metabolic programming, and the 
paracrine and autocrine signals that are involved in triggering and maintaining them 
(Caramel et al., 2013; Scheel et al., 2011; Tam and Weinberg, 2013). We foresee that future 
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research will identify additional markers that allow further classification of distinct 
intermediate epithelial-mesenchymal states, and provide insights into the activation and 
regulation of these various EMT programs in different tumor types and at distinct stages of 
tumor development (Outstanding questions). These results will likely open new avenues that 
should allow development of early detection strategies and more effective therapeutic 
targeting of malignant solid tumors.
Outstanding Questions
• What are the functionally important, distinct intermediate states along the 
epithelial-mesenchymal axis that naturally arise under physiological and 
pathological conditions, in particular during carcinoma progression?
• What are the features/markers that would allow identification of these 
intermediate states?
• Which of these states favors the formation of epithelial stem cells?
• Which combinations of EMT-associated transcription factors are responsible for 
organizing these distinct states?
• Which types of contextual signals and acting in various combinations serve 
physiologically to activate expression of EMT-inducing transcription factors 
and, in turn, entrance into more mesenchymal cell states?
• Are the close functional connections between the stem-cell state and the EMT 
program, which have been most thoroughly documented in the context of the 
mammary epithelium, also apparent in other epithelial tissues or do other 
principles govern EMT and stemness in other tissues?
• Do still-unidentified cell-biological programs act together with the EMT 
program to orchestrate entrance into and out of the epithelial stem-cell state?
• Is the mesenchymal-epithelial transition (MET) actively induced by specific 
signals, or is it simply a default process that occurs when EMT-inducing signals 
are absent?
• Why mechanistically is epithelial-mesenchymal plasticity critical for residence 
in the normal and neoplastic stem-cell states?
• How can the EMT program be reversed in order to eliminate therapy-resistance 
cancer stem cells?
Acknowledgments
R.A.W. is an American Cancer Society and Ludwig Foundation professor. This research was supported by the 
Breast Cancer Research Foundation, the Samuel Waxman Cancer Research Foundation, the Ludwig Center for 
Molecular Oncology at MIT, National Cancer Institute Program P01-CA080111, R01-CA078461, U01-CA184897 
(to R.A.W.), K99-CA194160 (to X.Y.), and the Helen Hay Whitney Foundation (to X.Y.).
Ye and Weinberg Page 12
Trends Cell Biol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
References
Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal 
transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009; 
119:1438–1449. [PubMed: 19487820] 
Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, 
Larsen AK, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma 
promote escape from T-cell-mediated lysis. Cancer Res. 2013; 73:2418–2427. [PubMed: 23436798] 
Akalay I, Tan TZ, Kumar P, Janji B, Mami-Chouaib F, Charpy C, Vielh P, Larsen AK, Thiery JP, 
Sabbah M, et al. Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer 
cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. Oncogene. 
2015; 34:2261–2271. [PubMed: 24931170] 
Aleskandarany MA, Negm OH, Green AR, Ahmed MA, Nolan CC, Tighe PJ, Ellis IO, Rakha EA. 
Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and 
reverse phase protein array study. Breast Cancer Res Treat. 2014; 145:339–348. [PubMed: 
24771047] 
Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, 
Andreeff M, et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage 
differentiation potential similar to mesenchymal stem cells. Stem cells. 2010; 28:1435–1445. 
[PubMed: 20572012] 
Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA. Correlation of 
Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 
2002; 21:3241–3246. [PubMed: 12082640] 
Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell. 2007; 128:445–
458. [PubMed: 17289566] 
Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW. Epithelial 
mesenchymal transition traits in human breast cancer cell lines. Clinical & experimental metastasis. 
2008; 25:629–642. [PubMed: 18461285] 
Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development 
and cancer? EMBO Rep. 2010; 11:670–677. [PubMed: 20706219] 
Brabletz T. MiR-34 and SNAIL: another double-negative feedback loop controlling cellular 
plasticity/EMT governed by p53. Cell cycle. 2012; 11:215–216. [PubMed: 22214667] 
Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal 
repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in 
cancer cells. EMBO Rep. 2008; 9:582–589. [PubMed: 18483486] 
Calabrese P, Tavare S, Shibata D. Pretumor progression: clonal evolution of human stem cell 
populations. Am J Pathol. 2004; 164:1337–1346. [PubMed: 15039221] 
Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, Chambers AF, 
MacDonald IC. Temporal progression of metastasis in lung: cell survival, dormancy, and location 
dependence of metastatic inefficiency. Cancer Res. 2000; 60:2541–2546. [PubMed: 10811137] 
Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, 
Hutchinson P, Tse G, et al. A switch in the expression of embryonic EMT-inducers drives the 
development of malignant melanoma. Cancer Cell. 2013; 24:466–480. [PubMed: 24075834] 
Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, 
Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-
like state. Proc Natl Acad Sci U S A. 2011; 108:7950–7955. [PubMed: 21498687] 
Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA, 
Weinberg RA. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and 
enhances tumorigenicity. Cell. 2013; 154:61–74. [PubMed: 23827675] 
Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO. Diversity, topographic 
differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A. 2002; 
99:12877–12882. [PubMed: 12297622] 
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic 
sites. Nat Rev Cancer. 2002; 2:563–572. [PubMed: 12154349] 
Ye and Weinberg Page 13
Trends Cell Biol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, 
et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 
expression and intratumoral immunosuppression. Nature communications. 2014; 5:5241.
Cheng Q, Chang JT, Gwin WR, Zhu J, Ambs S, Geradts J, Lyerly HK. A signature of epithelial-
mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in 
breast cancer independent of disease subtype. Breast cancer research : BCR. 2014; 16:407. 
[PubMed: 25060555] 
Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, Kim HJ, Lee HE, Park SY. Epithelial-
mesenchymal transition increases during the progression of in situ to invasive basal-like breast 
cancer. Human pathology. 2013; 44:2581–2589. [PubMed: 24055090] 
Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells 
and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010; 15:253–
260. [PubMed: 20354771] 
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez 
A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal 
as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106:13820–13825. [PubMed: 
19666588] 
Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978; 
38:2651–2660. [PubMed: 354778] 
Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev 
Cancer. 2003; 3:453–458. [PubMed: 12778135] 
Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial 
plasticity and metastasis. Nat Rev Mol Cell Biol. 2003; 4:657–665. [PubMed: 12923528] 
Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-
Hardi U, Bell G, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 
2012; 148:1015–1028. [PubMed: 22385965] 
Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state 
transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146:633–
644. [PubMed: 21854987] 
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of 
selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138:645–659. 
[PubMed: 19682730] 
Hay, ED. Organization and fine structure of epithelium and mesenchyme in the developing chick 
embryo. In: Fleischmajer, R.; Billingham, RE., editors. Epithelial-mesenchymal interactions. 
Baltimore: Williams and Wilkins; 1968. p. 31-55.
Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction 
in cancer. Int J Cancer. 2013; 132:745–754. [PubMed: 22753312] 
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during 
tumor progression. Curr Opin Cell Biol. 2005; 17:548–558. [PubMed: 16098727] 
Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, 
Riethmuller G, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13:58–
68. [PubMed: 18167340] 
Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel 
C, Velculescu VE, et al. Comparative lesion sequencing provides insights into tumor evolution. 
Proc Natl Acad Sci U S A. 2008; 105:4283–4288. [PubMed: 18337506] 
Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant 
molecular event in malignant gliomas. Cancer Lett. 2013; 331:131–138. [PubMed: 23268331] 
Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, et al. A 
p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. 
The Journal of cell biology. 2011; 195:417–433. [PubMed: 22024162] 
Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9:302–312. 
[PubMed: 19308069] 
Ye and Weinberg Page 14
Trends Cell Biol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through 
immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15:195–206. 
[PubMed: 19249678] 
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an 
epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011; 20:576–590. 
[PubMed: 22094253] 
Li HJ, Reinhardt F, Herschman HR, Weinberg RA. Cancer-stimulated mesenchymal stem cells create 
a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer discovery. 2012; 2:840–855. 
[PubMed: 22763855] 
Lin Y, Dong C, Zhou BP. Epigenetic regulation of EMT: the Snail story. Current pharmaceutical 
design. 2014; 20:1698–1705. [PubMed: 23888971] 
Lu H, Clauser KR, Tam WL, Frose J, Ye X, Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, 
Carr SA, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes 
and macrophages. Nat Cell Biol. 2014; 16:1105–1117. [PubMed: 25266422] 
Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. Multistep 
nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and 
limited survival of early micrometastases. Am J Pathol. 1998; 153:865–873. [PubMed: 9736035] 
Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J. 
Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 
2012; 481:85–89. [PubMed: 22158103] 
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, 
Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem 
cells. Cell. 2008; 133:704–715. [PubMed: 18485877] 
Massague J. TGFbeta in Cancer. Cell. 2008; 134:215–230. [PubMed: 18662538] 
Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff 
RD, Chodosh LA. The transcriptional repressor Snail promotes mammary tumor recurrence. 
Cancer Cell. 2005; 8:197–209. [PubMed: 16169465] 
Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-
Shisheboran M, Treilleux I, Tissier A, Gras B, et al. EMT inducers catalyze malignant 
transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors 
in transgenic mice. PLoS Genet. 2012; 8:e1002723. [PubMed: 22654675] 
Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem 
cells through epithelial-mesenchymal transition. PLoS One. 2008; 3:e2888. [PubMed: 18682804] 
Nakaya Y, Sheng G. Epithelial to mesenchymal transition during gastrulation: an embryological view. 
Development, growth & differentiation. 2008; 50:755–766.
Nassour M, Idoux-Gillet Y, Selmi A, Come C, Faraldo ML, Deugnier MA, Savagner P. Slug controls 
stem/progenitor cell growth dynamics during mammary gland morphogenesis. PLoS One. 2012; 
7:e53498. [PubMed: 23300933] 
Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu 
Rev Cell Dev Biol. 2011; 27:347–376. [PubMed: 21740232] 
Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013; 
342:1234850. [PubMed: 24202173] 
Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, 
Nieto MA. Metastatic colonization requires the repression of the epithelial-mesenchymal transition 
inducer Prrx1. Cancer Cell. 2012; 22:709–724. [PubMed: 23201163] 
Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and 
metastasis. Current biology : CB. 1998; 8:1243–1252. [PubMed: 9822576] 
Oliveras-Ferraros C, Corominas-Faja B, Cufi S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, 
Lopez-Bonet E, Martin AG, Menendez JA. Epithelial-to-mesenchymal transition (EMT) confers 
primary resistance to trastuzumab (Herceptin). Cell cycle. 2012; 11:4020–4032. [PubMed: 
22992620] 
Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, 
Spremberg F, Cortesi E, et al. Epithelial-mesenchymal transition and stemness features in 
Ye and Weinberg Page 15
Trends Cell Biol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 2011; 130:449–455. 
[PubMed: 21298334] 
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi 
AK, Vonderheide RH, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 
2012; 148:349–361. [PubMed: 22265420] 
Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, Tekmal RR, Vadlamudi 
RK. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast 
cancer. Oncogene. 2014; 33:3707–3716. [PubMed: 23975430] 
Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-
mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008; 
68:989–997. [PubMed: 18281472] 
Savagner P, Kusewitt DF, Carver EA, Magnino F, Choi C, Gridley T, Hudson LG. Developmental 
transcription factor slug is required for effective re-epithelialization by adult keratinocytes. J Cell 
Physiol. 2005; 202:858–866. [PubMed: 15389643] 
Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson 
AL, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in 
the breast. Cell. 2011; 145:926–940. [PubMed: 21663795] 
Schmidt JM, Panzilius E, Bartsch HS, Irmler M, Beckers J, Kari V, Linnemann JR, Dragoi D, Hirschi 
B, Kloos UJ, et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after 
transient Twist1 activation. Cell reports. 2015; 10:131–139. [PubMed: 25578726] 
Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, 
Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature. 2006; 
439:84–88. [PubMed: 16397499] 
Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB. 
An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular 
phenotype. PLoS genetics. 2011; 7:e1002218. [PubMed: 21876675] 
Shaul YD, Freinkman E, Comb WC, Cantor JR, Tam WL, Thiru P, Kim D, Kanarek N, Pacold ME, 
Chen WW, et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal 
transition. Cell. 2014; 158:1094–1109. [PubMed: 25171410] 
Shirley SH, Hudson LG, He J, Kusewitt DF. The skinny on Slug. Mol Carcinog. 2010; 49:851–861. 
[PubMed: 20721976] 
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war 
on cancer. Oncogene. 2010; 29:4741–4751. [PubMed: 20531305] 
Stankic M, Pavlovic S, Chin Y, Brogi E, Padua D, Norton L, Massague J, Benezra R. TGF-beta-Id1 
signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial 
transition. Cell reports. 2013; 5:1228–1242. [PubMed: 24332369] 
Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and 
unique properties of mammary epithelial stem cells. Nature. 2006; 439:993–997. [PubMed: 
16395311] 
Su S, Liu Q, Chen J, Chen F, He C, Huang D, Wu W, Lin L, Huang W, Zhang J, et al. A positive 
feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast 
cancer metastasis. Cancer Cell. 2014; 25:605–620. [PubMed: 24823638] 
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult 
fibroblast cultures by defined factors. Cell. 2006; 126:663–676. [PubMed: 16904174] 
Tam PP, Behringer RR. Mouse gastrulation: the formation of a mammalian body plan. Mechanisms of 
development. 1997; 68:3–25. [PubMed: 9431800] 
Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 
2013; 19:1438–1449. [PubMed: 24202396] 
Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. 
Cancer Res. 2005; 65:5996–6000. discussion 6000–5991. [PubMed: 16024596] 
Theveneau E, Marchant L, Kuriyama S, Gull M, Moepps B, Parsons M, Mayor R. Collective 
chemotaxis requires contact-dependent cell polarity. Developmental cell. 2010; 19:39–53. 
[PubMed: 20643349] 
Ye and Weinberg Page 16
Trends Cell Biol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2:442–
454. [PubMed: 12189386] 
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and 
disease. Cell. 2009; 139:871–890. [PubMed: 19945376] 
Tran HD, Luitel K, Kim M, Zhang K, Longmore GD, Tran DD. Transient SNAIL1 expression is 
necessary for metastatic competence in breast cancer. Cancer Res. 2014; 74:6330–6340. [PubMed: 
25164016] 
Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-
mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell. 2012; 
22:725–736. [PubMed: 23201165] 
Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau 
LM, et al. Primary glioblastomas express mesenchymal stem-like properties. Molecular cancer 
research : MCR. 2006; 4:607–619. [PubMed: 16966431] 
Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is 
required for inflammation-induced cell migration and invasion. Cancer Cell. 2009; 15:416–428. 
[PubMed: 19411070] 
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, 
Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role 
in tumor metastasis. Cell. 2004; 117:927–939. [PubMed: 15210113] 
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, 
Ruotti V, Stewart R, et al. Induced pluripotent stem cell lines derived from human somatic cells. 
Science. 2007; 318:1917–1920. [PubMed: 18029452] 
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah 
AM, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal 
composition. Science. 2013; 339:580–584. [PubMed: 23372014] 
Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, Keely PJ, Longmore GD. 
The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer 
metastasis. Nat Cell Biol. 2013; 15:677–687. [PubMed: 23644467] 
Ye and Weinberg Page 17
Trends Cell Biol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Trends Box
• The Epithelial-mesenchymal transition (EMT) program is a naturally occurring 
transdifferentiation program that governs changes of cell states along the 
epithelial versus mesenchymal axis and confers upon epithelial cells epithelial-
mesenchymal plasticity.
• Activation of the EMT program places normal and neoplastic epithelial cells in 
states where they are poised to enter into stem cell compartments.
• During development and cancer pathogenesis, the EMT program is induced by a 
number of synergistic contextual signals.
• Epithelial-mesenchymal plasticity is critical for carcinoma progression and 
metastasis. Inhibition of EMT activation and/or epithelial-mesenchymal 
plasticity may serve as new ways to clinically treat advanced carcinomas.
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Fig. 1. EMT-inducing signals in the tumor microenvironment
During the process of tumor progression, the EMT program is induced and maintained 
through concerted actions of a number of stroma-derived paracrine and juxtacrine signals.
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